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Congenital muscular dystrophy is a heterogeneous group of inherited muscle diseases characterized clinically by muscle weakness and
hypotonia in early infancy. A number of genes harboring causative mutations have been identified, but several cases of congenital
muscular dystrophy remain molecularly unresolved. We examined 15 individuals with a congenital muscular dystrophy characterized
by early-onset muscle wasting, mental retardation, and peculiar enlarged mitochondria that are prevalent toward the periphery of the
fibers but are sparse in the center on muscle biopsy, and we have identified homozygous or compound heterozygous mutations in the
gene encoding choline kinase beta (CHKB). This is the first enzymatic step in a biosynthetic pathway for phosphatidylcholine, the most
abundant phospholipid in eukaryotes. In muscle of three affected individuals with nonsense mutations, choline kinase activities were
undetectable, and phosphatidylcholine levels were decreased. We identified the human disease caused by disruption of a phospholipid
de novo biosynthetic pathway, demonstrating the pivotal role of phosphatidylcholine in muscle and brain.A spontaneous mutant mouse with a neonatal-onset auto-
somal-recessive rostral-to-caudal muscular dystrophy (rmd
mouse) due to a loss-of-function mutation in choline
kinase beta (Chkb) was identified in 2006.1 Interestingly,
rmd mice exhibit a unique mitochondrial morphology in
muscle fibers, which show enlarged mitochondria at the
periphery of the fiber but none at the center (Figure S1).
These features are similar to those seen in a congenital
muscular dystrophy (CMD) that we previously reported
in four Japanese individuals.2 We therefore screened 15
genetically undiagnosed cases of CMD with fairly homog-
enous clinical features (Table 1) for mutations in choline
kinase beta (CHKB); we included the four cases from in
our previous study in these 15 cases. Features included
peculiar mitochondrial changes in muscle as well as motor
delay followed by the appearance of severe mental retarda-
tion and microcephaly without structural brain abnormal-
ities (Figure 1 and Table 1).
All clinical materials used in this study were obtained for
diagnostic purposes with written informed consent. The
study was approved by the Ethical Committee of the
National Center of Neurology and Psychiatry. All mouse
protocols were approved by the Ethical Review Committee
on the Care and Use of Rodents in the National Institute of
Neuroscience, National Center of Neurology and Psychi-1National Institute of Neuroscience, Department of Neuromuscular Researc
2Department of Pediatrics, Pathology Unit, Hacettepe Children’s Hospital, Ank
Tokyo, 1088641, Japan; 4Department of Biochemistry, Dokkyo Medical Unive
The Kanagawa Rehabilitation Center, Kanagawa, 2430121, Japan; 6Dubowitz N
London, WC1N 3JH, UK; 7MRC Centre for Neuromuscular Disorders, Nationa
3BG, UK; 8RJAH Orthopaedic Hospital, Oswestry, SY107AG, UK; 9Departmen
Tokyo, 1130033, Japan; 10The Jackson Laboratory, Bar Harbor, Maine, 04609, U
Hospital, 06100, Ankara, Turkey
*Correspondence: nishino@ncnp.go.jp
DOI 10.1016/j.ajhg.2011.05.010. 2011 by The American Society of Human
The Ameatry. For muscle pathology, samples of skeletal muscle
were obtained from biceps brachii or quadriceps femoris
in humans and from quadriceps femoris muscle in
8-week-old rmd mice. Muscles were frozen and sectioned
at a thickness of 10 mm according to standard procedures,
and a battery of routine histochemical stains, including
hematoxylin and eosin (H&E), modified Gomori tri-
chrome (mGT), NADH-tetrazolium reductase (NADH-TR),
succinate dehydrogenase (SDH), cytochrome c oxidase
(COX), and Oil Red O, were analyzed. For electron micro-
scopic analysis, muscles were fixed as previously
described,3 and ultra-thin sections were observed at
120kV or 80kV. All affected individuals exhibited nonspe-
cific dystrophic features (Figure 1A). However, in mGT,
NADH-TR, SDH, and COX staining, prominent mitochon-
dria at the periphery as well as central areas devoid of
mitochondria were seen (Figures 1B and 1C). Oil Red O
staining was unremarkable (data not shown). Electron
microscopy confirmed enlarged mitochondria (Figure 1D).
We directly sequenced all exons and their flanking
intronic regions in CHKB (MIM 612395, NM_005198.4,
GenBank Gene ID 1120) in genomic DNA extracted from
individuals’ peripheral lymphocytes. All 15 individuals in
three different populations (Japanese, Turkish, and British)
had homozygous or compound heterozygousmutations inh, National Center of Neurology and Psychiatry, Tokyo 1878502, Japan;
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Table 1. Summary of Clinical and Laboratory Features
Phenotypic Findings Muscle Pathology Mutations
Indivi-
dual Sex Origin
Age at Last
Follow-Up
Floppy
at Birth
Walk
Alone
Serum
Creatine
Kinase
(IU/liter)
Head
Circumference
(percentile)
Mental
Retar-
dation Seizure
Cardiomyo-
pathy
Skin
Change
Age at
Muscle
Biopsy
Necrotic
Fiber
Regener-
ative
Fiber
Endo-
mysial
Fibrosis
Mitochon-
drial
Enlarge-
ment Status cDNA Consequence Exon
Literature
ref. on
phenotype
1 F Japanese died at
13 yr
þ 2 yr 6 mo 370 ND þ - þ - 7 yr3 mo þ þ þ þ homo c.810T>A p.Tyr270X 7 2
2 M Japanese died at
23 yr
þ 1 yr 9 mo 190–2676 25–50 þ þ þ - 1 yr 2 mo þ þ þ þ homo c.810T>A p.Tyr270X 7 2
3 F Japanese 28 yr þ 1 yr 6 mo 502 ND þ þ þ - 8 yr þ þ þ þ het c.116C>A p.Ser39X 1 2
het c.458dup p.Leu153PhefsX57 3 2
4 M Japanese 22 yr þ 2 yr 6 mo 230 3–10 þ þ - - 4 yr 11 mo þ þ þ þ het c.116C>A p.Ser39X 1
het c.458dup p.Leu153PhefsX57 3
5 M Turkish 7 yr - 2 yr 6 mo 843 <3 þ - - þ 6 yr 5 þ þ þ homo c.611_612insC p.Thr205AsnfsX5 5
6a M Turkish died at
2 yr 6 mo
þ no 258 <3 þ - þ - 1 yr 3 mo 5 5 þ þ homo c.922C>T p.Gln308X 8
7 F Turkish 2 yr - no 368 3-10 þ - -b - 9 mo - 5 þ þ homo c.847G>A p.Glu283Lys 8
8 M Turkish 13 yr ND 2 yr 1122 ND þ - - - 12 yr
10 mo
5 5 þ þ homo c.1130 G>T p.Arg377Leu 11
9 F Turkish 17 yr þ 3 yr 2669 <3 þ - ND - 17 yr 5 5 þ þ homo c.554_562del p.Pro185_Trp187del 4
10 F Turkish 16 yr þ 3 yr 1103 <3 þ - -c þ 3 yr - 5 þ þ homo c.677þ1G>A ND 5
11 F Turkish 3 yr 3 mo þ no 497 10-25 þ - ND - 3 yr 5 - þ þ homo c.677þ1G>A ND 5
12 F Turkish 5 yr - 3 yr 6 mo 467 25–50 þ - -d þ 4 yr 6 mo 5 þ þ þ homo c.677þ1G>A ND 5
13 M Turkish 3 yr 6 mo þ no 428 <3 þ - þ þ 3 yr þ þ þ þ homo c.1031þ1G>A aberrant splicing 9
14 F Turkish 6 yr 4 mo - 1 yr 3 mo 1606 3–10 þ - þ - 4 yr þ þ þ þ homo c.1031þ1G>A ND 9
15 M British died at
8 yr
- 3 yr 4 mo 607–1715 <3 þ - þ þ 2 yr 2 mo þ - þ þ homo c.852_859del p.Trp284X 8
Detailed clinical information for individual 1 to 4 was previously described (2). Eleven CHKB mutations were identified in 15 affected individuals. All exhibited generalized muscle hypotonia and weakness from early infancy.
Ambulation was delayed, and gait in those who achieved walking was limited. In addition, all displayed marked mental retardation, and most never acquired meaningful language. Microcephaly with head circumferences at
or below the 3rd to 10th percentile was observed in most cases. Cranial magnetic resonance imaging showed no developmental brain defects. Six individuals had dilated cardiomyopathy, and two had cardiac anomaly.
Individuals 1, 2, 6, and 15 died from cardiomyopathy at ages 13 yr, 23 yr, 2 yr 6 mo, and 8 yr, respectively. No one had respiratory insufficiency. Ichthyosiform skin changes were frequent. All showed mildly to moderately
elevated serum creatine kinase (CK) levels. Individuals 7 and 9 also had homozygous single-nucleotide substitutions, c.902C>T (p.Thr301Ile) and c.983A>G (p.Gln328Arg), respectively. CHK activities of recombinant CHK-
b proteins with p.Thr301Ile and p.Gln328Arg were only mildly decreased (Figure S2), suggesting these are likely to be neutral polymorphisms or only mildly hypomorphic mutations. Individuals 10, 11, and 12, who have
same c.677þ1G>A mutation, and individuals 13 and 14, who have same c.1031þ1G>A mutation, are not siblings. Abbreviations are as follows: ND, not determined; p, percentile; F, female; and M, male.
a An affected sibling had ichthyosis and died at age 6 years with cardiomyopathy.
b Patent ductus arteriosus.
c Atrial septal defect.
d Mitral valve prolapse.
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Figure 1. Muscle Pathology of the Affected
Individuals
Cross-sections of muscle fiber from a human
control and individual 4.
(A) On H&E staining, nonspecific dystrophic
features with necrotic and regenerating fibers,
internalized nuclei, and endomysial fibrosis are
seen. The scale bar represents 25 mm.
(B) On cytochrome c oxidase staining, enlarged
mitochondria at the periphery and central areas
devoid of mitochondria were seen. The scale bar
represents 20 mm.
(C) On NADH-TR staining, the intermyofibrillar
network was preserved even in the central areas
that are devoid of mitochondria, suggesting the
presence of myofibrils and only absence of mito-
chondria. The scale bar represents 20 mm.
(D) Electron microscopy confirmed enlarged
mitochondria. The scale bar represents 1 mm.CHKB (Table 1). Among a total of 11 mutations identified,
six were nonsense, two were missense, one was a 3 amino
acid deletion, and two were splice-site mutations. The six
nonsense mutations, c.116C>A (p.Ser39X), c.458dup
(p.Leu153PhefsX57), c.611_612insC (p.Thr205AsnfsX5),
c.810T>A (p.Tyr270X), c.852_859del (p.Trp284X), and
c.922C>T (p.Gln308X), were predicted to truncate the
protein and eliminate highly conserved domains of
CHK.4,5 Individuals 1 and 2 (unrelated, Japanese) had the
same homozygous nonsense mutation of c.810T>A
(p.Tyr270X). Individual 2’s mother, who was healthy,
had the heterozygous c.810T>A (p.Tyr270X) mutation.
Unfortunately, a DNA sample from the father of individual
2 was not available. DNA samples from other familyThe American Journal of Hmembers of individual 1 and 2 were not
available. Individuals 3 and 4 (siblings,
Japanese) had the same compound hetero-
zygous mutation c.116C>A (p.Ser39X)
and c.458dup (p.Leu153PhefsX57). Both
parents were healthy, and the father was
heterozygous for mutation c.116C>A
(p.Ser39X), whereas the mother was hetero-
zygous for mutation c. 458dup (p.Leu153-
PhefsX57), thus confirming a recessive
inheritance pattern. These mutations cose-
gregated with the disease phenotype in all
family members tested.
We thereforemeasuredCHKactivity in bi-
opsiedmuscle. For all biochemical analyses,
because of the limiting amounts of remain-
ing tissue, biopsied muscle samples were
available only from individuals 2, 3, and 4.
Biopsied muscle samples from these three
individualswere homogenized in 3 volumes
of 20 mM Tris-HCl (pH 7.5), 154 mM KCl,
and 1 mM phenylmethanesulfonyl fluoride
with a sonicator (MISONIX), and superna-
tant fractions (105,000 3 g, 60 min) were
prepared and analyzed for CHK activity aspreviously described.6 Similar to muscles of rmd mice,1
muscles from individuals 2, 3, and 4, who carried homozy-
gous or compound heterozygous nonsense mutations, did
not have any detectable CHK activity (Figure 2A). Individ-
uals 7, 8, and 9 had homozygous missense mutations
c.847G>A (p.Glu283Lys) and c.1130 G>T (p.Arg377Leu)
and a homozygous 3 amino acid deletion, c.554_562 del
(p.Pro185_Trp187del), respectively.We screened 210 con-
trol chromosomes for the identified missense mutations
and small in-frame deletion by direct sequencing or
single-strand conformationpolymorphism (SSCP) analysis.
SSCPwasperformedwithGeneGel Excel (GEHealthcare) as
previously described.7 These missense mutations and this
small in-frame deletion were not identified in controluman Genetics 88, 845–851, June 10, 2011 847
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Figure 2. Choline Kinase Activity and Phospholipid Analyses
(A) In muscle tissue from individuals 2, 3, and 4, CHK activity cannot be detected (n ¼ 3). Data represent the mean of three individuals.
(B) PC and PE content in frozen biopsied muscle tissues from individuals 2, 3, and 4 and hindlimb muscles from 8-week-old rmd mice
(n ¼ 4) and control littermates (n¼ 5) were analyzed by thin-layer chromatography followed by phosphorus analysis. PC and the PC/PE
ratio are significantly decreased in affected individuals and rmd mice (n ¼ 3 for humans, n ¼ 4 for rmd mice, n ¼ 5 for littermates).
(C) Fatty acid composition of PC molecular species in muscles and isolated mitochondria from hindlimb muscles of rmdmice are deter-
mined by electrospray ionization mass spectrometry (ESI-MS). We observed that 34:1-PC (16:0-18:1), 36:4-PC (16:0-20:4), and 38:6-PC
(16:0-22:6) species are significantly decreased, whereas 36:2-PC (18:0-18:2) is increased in rmd muscle. Similarly, in isolated mitochon-
dria from hindlimb muscle, 36:4-PC (16:0-20:4) and 38:6-PC (16:0-22:6) species are decreased, whereas 36:2-PC (18:0-18:2) is increased.
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chromosomes. To elucidate the pathogenesis of these
substitutions, we measured CHK activity in recombinant
proteinswithmutations.Wecloned theopen reading frame
of CHKB into pGEM-T easy (Promega), then subcloned it
into pET15b (Novagen) to make His-tagged CHK-b.8 Each
mutation was induced by site-directed mutagenesis.7 Plas-
mids were transformed into Escherichia coli strain BL21
(DE3) and inoculated at 20C to anOD600 of approximately
0.5, and the addition of 0.4mM isopropyl-b-D-thiogalacto-
pyranoside induced expression. The His-tagged CHK-
b proteins were subjected to affinity purification on a nickel
column (GE Healthcare) and eluted with 20 mM Tris-HCl
(pH 7.4), 0.5MNaCl, 300mM imidazol, and 1mMphenyl-
methanesulfonyl fluoride, and 25 ng protein was analyzed
for CHK activity. CHK activity of recombinant proteins
with these mutations decreased to less than 30% of wild-
typeCHKactivity, suggesting that thesemutations are caus-
ative in these individuals (Figure S2). For individual 13,who
had a mutation at the splice site of the exon-intron border
after exon 9 (c.1031þ1G>A), we also analyzed cDNA
sequences. Exons 4 through 10 were amplified from the
first-strand cDNAs, and direct sequencing followed. cDNA
analysis of CHKB in skeletal muscle from individual 13
showed four splicing variants, all of which remove
consensus domains for CHKB (Figure S3). This suggests the
same loss-of-functionmechanism inhumansand rmdmice.
Because phosphorylation of choline by CHK is the first
enzymatic step for phosphatidylcholine (PC) biosyn-
thesis,9 we anticipated that PC content should be altered
in affected individuals’ muscles. Phosphatidylcholine
(PC), phosphatidylethanolamine (PE), and total phospho-
lipid amounts were measured in biopsied muscles
from individuals 2, 3, and 4 and in leg muscles from
8-week-old rmd mice by either one-dimensional or
two-dimensional thin-layer chromatography (TLC) fol-
lowed by phosphorus analysis.10,11 As expected, PC levels
decreased in affected individuals’ skeletal muscle
(Figure 2B), as they did in rmd mice (Figure 2B and Sher
et al.1), suggesting that the CMDs due to CHKB mutations
in humans and rmd mice are not only pathologically but
also pathomechanistically similar.
PC is present in all tissues and accounts for around 50%
of phospholipids in biological membranes in eukaryotes.
Selective tissue involvement can be explained by the
different tissue distribution of CHK isoforms. There are
two CHK isoforms: CHK-a and CHK-b, encoded by distinct
genes, CHKA (MIM 118491) and CHKB, respectively. TheyIn muscle and isolated mitochondria, the 38:6-PC molecular species
chondria).
Mitochondria from skeletal muscles of whole hindlimbs of rmd mi
muscle was minced and homogenized with a motor-driven Teflon
(10 mM Tris-HCl [pH 7.2], 320 mM sucrose, 1mM EDTA, 1mMDTT, 1
and centrifuged at 1,5003 g for 5 min. The supernatant fraction was
mitochondrial isolation buffer, and the centrifugation/resuspension
All data are presented as means 5 standard deviation (SD). Means
version 2.11.0.
The Ameare known to form both homodimers and heterodimers,
with differential tissue distribution.12 In mice, disruption
of Chka causes embryonic lethality,13 suggesting the
importance of CHK-a in embryonic development. In skel-
etal muscles from rmdmice, CHK activity is absent, and PC
levels are decreased.1 In other tissues, however, CHK
activity is only mildly decreased, PC levels are not altered,
and no obvious pathological change is seen.1 CHK activity
in skeletal muscle from individuals 2, 3, and 4 is barely
detectable, and PC levels are significantly decreased, sug-
gesting that CHK-b is the major isoform in human skeletal
muscle. In support of this notion, CHK-a was not detected
in human muscle (Figure S4). These results suggest that
muscular dystrophy in affected individuals and rmd mice
is caused by a defect in muscle PC biosynthesis. In addi-
tion, in rmdmice, hindlimb muscles are more significantly
affected than forelimb muscles.1 This is most likely ex-
plained by the fact that CHK activity is detected, though
decreased, in forelimb muscles in rmd mice as a result of
the continued post-natal expression of Chka.14 This indi-
cates that the severity of muscle involvement is deter-
mined by the degree of deficiency of CHK activity.
Generally, phospholipids have saturated or monounsat-
urated fatty acids at the sn-1 position and polyunsaturated
fatty acids at the sn-2 position of glycerol backbone.15 It
has been shown that phospholipids have tissue-specific
fatty acid composition.15 For example, heart PC and
muscle PC mainly contain docosahexaenoic acid (22:6)
(Nakanishi et al.15 and Figure 2C), but liver PC includes
various fatty acids.15 NanoESI-MS analyses of PCmolecular
species in muscle and isolated mitochondria were per-
formed with a 4000Q TRAP (AB SCIEX, Foster City, CA,
USA) and a chip-based ionization source, TriVersa Nano-
Mate (Advion BioSystems, Ithaca, NY, USA).16 Quadriceps
femoris (hindlimb) and Triceps (forelimb) muscle from
affected rmd mice and littermate controls were frozen
with liquid nitrogen, and total lipid was extracted by the
Bligh and Dyer method.10 The ion spray voltage was set
at 1.25kV, gas pressure at 0.3 pound per square inch
(psi), and flow rates at 200 nl/min. The scan range was
set at m/z 400~1200, declustering potential at100V, colli-
sion energies at 35~45V, and resolutions at Q1 and Q3
‘‘unit.’’ The mobile phase composition was chloroform:
methanol (1/2) containing 5 mM ammonium formate
and was normalized to the muscle weight. The total lipids
were directly subjected by flow injection, and selectivity
was analyzed by neutral loss scanning of the polar headis profoundly decreased (n ¼ 6 for muscle, n ¼ 5 for isolated mito-
ce were isolated by the differential centrifugation method. Fresh
pestle homogenizer with ice-cold mitochondrial isolation buffer
mM PMSF, 1 mg/ml BSA, and protease inhibitor cocktail [Roche])
centrifuged at 15,0003 g for 20 min, the pellet was resuspended in
was repeated twice more.
were compared by analysis with a two-tailed t test via R software
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group for PC in negative-ion mode.17 Interestingly, there
was a 10-fold decrease (9.8%) in the 16:0-22:6-PC levels
versus the control in rmd hindlimb muscle and also in
muscle mitochondria (Figure 2C), indicating the impor-
tance of the PC de novo synthesis pathway for maintain-
ing not only PC levels but also fatty acid composition of
PC molecular species. Similarly, in forelimb muscle 16:0-
22:6 PC levels were also decreased in comparison to the
control, but to a milder extent (18.2%), suggesting an asso-
ciation between severity of muscle damage and fatty acid
composition alteration of PC (data not shown). In rmd
mice, it has been shown that muscle PC can be delivered
from plasma lipoprotein,18 suggesting that non-decreased
PC molecular species might be derived from the plasma,
whereas 16:0-22:6 PCmight be synthesized only in muscle
(and possibly in brain). However, confirmation of this
requires further studies.
Individuals with CHKB mutations have severe mental
retardation in addition to the muscular dystrophy. Inter-
estingly, polymorphisms near the CHKB locus and
decreased CHKB expression have been associated with
narcolepsy with cataplexy, suggesting a link between
CHK-b activity and the maintenance of normal brain func-
tion in humans.19 Furthermore, brain damage in pneumo-
coccal infection has been attributed to the inhibition of de
novo PC synthesis, suggesting the importance of PC
synthesis for the brain.20 Our data provide evidence that
altered phospholipid biosynthesis is a causative agent for
a human congenital muscular dystrophy, and further
studies will elucidate the detailed molecular mechanisms
of the disease in both muscle and brain.Supplemental Data
Supplemental Data include four figures and can be foundwith this
article online at http://www.cell.com/AJHG/.Acknowledgments
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